Court Monitor • Feb 26, 2013

Should DNA Be Patentable?

Text Reader

This spring the U.S. Supreme Court will address this enigmatic question: "are human genes patentable?" Association for Molecular Pathology v. Myriad Genetics, No. 12-398. A simple question, but it has vast implications. Genes are part of everyone's "DNA," the building blocks of life. An individual's DNA can predict which diseases he is vulnerable to, and what treatment options are likely to work best. A company in Utah, Myriad Genetics, obtained patents relating to the two most famous human genes: BRCA1 and BRCA2, which are correlated to an increased risk of breast and ovarian cancer. Women can be tested to see if they have either gene, and then be on guard against the higher associated risk. Those having either gene, and a family history of breast cancer before age 50 and ovarian cancer, are more than 50% likely to develop breast cancer before age 50 and ovarian cancer. Myriad Genetics obtained patents by isolating these genes away from the human body, and these patents were upheld by the U.S. Court of Appeals for the Federal Circuit against a challenge by the ACLU and the Public Patent Foundation. The president of Myriad Genetics applauded its victory with the observation that "the Court agreed with Myriad that isolated DNA is a new chemical matter with important utilities which can only exist as the product of human ingenuity." But an appeal followed, and the Supreme Court took this case. At stake is billions of dollars in investment for testing, diagnosing, and treating patients who have genes more susceptible to cancer and other diseases. The opponents of allowing patents on isolated DNA insist that this is not patentable subject matter. But Myriad Genetics and its supporters observe that patents encourage more investment and innovation in identifying genetic issues and developing ways to treat defects. Initially, the Obama Administration sided with Myriad Genetics in defending the patents, which had been issued by the U.S. Patent and Trademark Office. But then the Obama Administration reversed itself and stopped defending the patents, perhaps sensing a political connection between this issue and its campaign rhetoric about a supposed "War on Women." The DNA in this particular case is associated more with cancer in women than in men and, with demagoguery, it can appear that someone is trying to profit by exploiting women who are in poor health. In fact, of course, women typically live much longer than men do. Patents have made the United States the world's leader in innovation, and 95% of all valuable inventions are achieved and developed here. But where there is no financial incentive to attract investment, no investment occurs. Corporations have a duty to shareholders to maximize profit, and no company would spend a billion dollars on something that can be copied by a competitor as soon as it appears on the market. There are places where patents do not exist, such as Communist China, and the result is almost no innovation. Denying the possibility of patenting isolated genes may slow down, rather than encourage, lifesaving work in genetics.